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Any believable prediction will be wrong. Any correct
prediction will be unbelievable. Either way, a futurist
can’t win. He is either dismissed or wrong … Most
people, particularly most smart people … will err on
the side of not being fantastical enough. Because
absolutely no one wants to be dismissed. What’s the
point of making a prediction if no one is listening? So
99% of future predictions will fall short of the nec-
essary unreasonableness for a correct prediction.
–Kevin Kelly, building on Arthur C. Clarke.
Sanjay shuffled bleary-eyed into the expansive kitchen.
‘‘Lordy,’’ he groaned. One-thirty in the afternoon. Well,
New Year’s Eve comes but once a year. Pouring himself
some coffee, he sat at the table and took stock, his natural
analytic bent slowly fighting to re-establish dominance.
Through the floor to ceiling windows he looked out over a
grey and gloomy London cityscape.
2037 was shaping up to be an important year for him.
Although he was a widely respected academic, with a high
Q-index, great SciDigg scores, three successful tenure
renewals, and excellent student references, he knew that the
game was changing. The world healthcare agency that was
funding 80% of his lab was particularly interested in psychi-
atric illnesses. And he knew his chances of getting his biggest
grant renewed next year were pretty poor if he didn’t come up
with something good. He was among the best known of the
‘‘crossover chemists’’—academic drug-hunters—and he had
been paid handsomely for his past successes. But the bar was
being raised: while in the past his rewards had come from
finding leads, all the multi-national agencies (and the few
remaining drug companies) were much more focused these
days on clinical successes. Just coming up with cool new
compounds didn’t get you very far any more. At this very
moment, in fact, he had seven half-written grant proposals on
his desk, all due by the end of the month. Hard to believe how
much more time-consuming it was lately to scrounge for grant
money than when he had started his career a quarter-century
earlier. Those were fat times, indeed! Now he knew that if he
didn’t keep up, even someone as well known as he was faced a
real risk of losing his tenure at the end of his current 5-year
contract.
At the New Year’s party he had run into that nerdy simu-
lator from the adaptive systems pharmacology department
who had been arguing strongly that he knew how to treat a
particular 11% subset of the gamma-type schizophrenics that
had a very characteristic epigenetic pattern in the CA1b hip-
pocampal subfield. It was simple, the kid said—just shut down
the mitochondrial biogenesis program by 40 to 70%
(depending on the severity of the heteroplasmic mutations and
the haplogroup of each specific patient) while allosterically
potentiating the f5GABAc receptor by three- to fourfold. ‘‘Just
block these three targets’’—the kid rattled them off—‘‘and
you’d normalize the pathways.’’ Sanjay only remembered this
much because his voice recorders had logged the conversation
and sent him a transcript. As memory slowly returned, Sanjay
recalled being amused by the nerd, who was barely out of
school and talked very fast, waving his arms wildly as he made
his case with complete confidence. He had seen a lot of kids
like that in his time. Usually they flamed out long before their
first tenure decision.
Sanjay pulled up the auto-assistant. The windows
automatically darkened and a set of icons appeared floating
in front of his face. As always, it first updated him on his 37
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students scattered around the globe. The status panel was
mostly green—no major problems—although, of course,
the dozen UK-based students were listed as ‘‘on holiday.’’
Impossible to get the lazy buggers to work more than the
contractual 80 hour per week minimum. The usual handful
of problem students were glowing amber or red. He sighed.
It was nice that universities had adopted a much more
networked, virtual model in the 2020s, but occasionally he
wondered whether the lack of direct contact hindered his
ability to train people. The holographic projection systems
and virtual lab assistants were fantastic—he couldn’t blame
those. But it just seemed that there were always a few
students who needed more personal attention and he
couldn’t fly them from Japan or Brazil very often. He put
all thoughts of his students aside and dismissed the status
panel.
He issued a voice command and then gestured in the
air. After a few seconds, brightly colored three-dimen-
sional images of the relevant pathways appeared in front
of him. Touching any node in the pathway brought up a
brief synopsis of key literature findings around a specific
target, as well as chemical structures of molecules that
modulated the activity of each target. Requirements for
electronic submission of chemical structures and data
accompanying any journal submission had been instituted
in 2021. Back in the 2010’s there had been a significant
backlash due to the inability of researchers to reproduce
scientific results from across all the disciplines, but
computational papers were uniformly the worst. The
resulting near-total breakdown (highlighted by several
leading academics being fired for incompetence and out-
right fraud) finally brought about an emphasis on repro-
ducibility and a new willingness among computational
chemists and biologists to create a shared software
infrastructure and develop software tools that could be
easily enhanced and integrated. This level of collaboration
led to the development of standard ontologies and to the
first practical applications of the semantic web.
After a half-hour of fiddling, Sanjay was reasonably
confident that he had found a three-drug combination that,
while not perfect, had a reasonable enough profile to enable
testing the nerd’s hypothesis. He was able to quickly link
each of these compounds to suppliers around the world and
found two in stock. Bots connected to five additional
suppliers instantly submitted bids for the synthesis of the
third compound. Sanjay reviewed their ratings on Amazon
and chose a small company in the Greater Australian
Confederation. Advances in microfluidics and flow chem-
istry had created a cottage industry for chemical synthesis.
Like everyone in the drug discovery game, Sanjay worked
through an extended network of collaborators and con-
tractors whenever possible. His students around the world
could take over whenever the vendors crapped out.
Having settled the synthesis issue, Sanjay thought it
would be worthwhile to see what else he could learn about
these pathways. A Google search found a group in
Argentina that could run their virtual pharmacology assay
on this mixture. He was in luck—he even knew the PI—
they had done their post-docs in the same department. A
quick video chat followed and Paolo offered to do it within
a few days. Sanjay sipped his coffee in satisfaction. Off in
the distance, near Big Ben, he saw the artificial fog rise
from the Thames. ‘‘Keeps the tourists happy,’’ he chuckled.
On the afternoon of January 4th he got a vidgram from
Paolo, who was quite excited. The results looked quite
good—the mitochondrial pathway seemed highly relevant.
Paolo added that this was consistent with some other recent
results he’d just obtained. Sanjay toggled the telepresence
feature on his iPhone (standard since IOS 27.2) and he and
Paolo were instantly ‘‘together’’ examining a set of images
from the virtual pharmacology study. As the images of the
treatment group streamed by, Paolo touched one to bring
up a hologram of the computer simulation of the action of
these compounds on the brains of both humans and the
three species of humanized primates. As Paolo rotated the
image and focused on the hippocampus, Sanjay could see
the model predicted the desired phenotypic effect based on
the downregulation of the targeted pathways. The two then
reviewed the range of probable outcomes in the standard
behavioral models. Advances in pattern recognition and
sensor technologies had largely reduced behavioral phar-
macology to an objective set of scores, but Paolo still liked
to review the video. By the end of the conversation Sanjay
was convinced that the virtual model was quite robust and
there was something here. Paolo cautioned that the model
was not teaching anything about the specifics of the best
ways to block the pathway, just that it played an important
role in this subset of schizophrenics.
After thanking Paolo and signing off, Sanjay stared out
the window of his office. This felt like a potential break-
through. Even now, in an era when everyone was so proud
of how efficient drug discovery had become, new insights
into disease biology were precious—the bottleneck for all
new therapy, same as had been true for his entire career. It
wasn’t that some chemical design problems weren’t still a
bit challenging, but the old fears of undruggable targets had
long since disappeared, and he had learned to follow the
biology wherever it led him. It was conceivable, he
thought, that he might eventually want to put a combina-
tion of these three compounds into some test subjects. At
least, he thought, this was a more enjoyable way to spend
the afternoon than fixing the problem with his grad student
in Malaysia. So he looked more closely at the properties of
those three compounds, trying to anticipate how he could
deliver them as a combo via nanobot. He set up a
quick simulation, and while it was running, he had the
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auto-assistant dig more deeply into the literature around the
synthesis of these compounds.
The AA started by running a search against Science-
Digg. In the early 2020s, scientists had tired of the politics
surrounding journal publication and simply begun blogging
their results. The thousands of scientific blogs created a
great deal of confusion and made it difficult to find the best
science. In an attempt to identify the highest quality work,
Science Magazine merged with Digg.com, to create a
system that allowed scientists around the world to rate the
work of their peers. A few assistant professors seeking
tenure had initially tried to game the system by voting with
bots, but the clever folks at Digg had dealt with that sort of
thing before. By 2027 ScienceDigg had become so
embedded that the Nordic Royal Academy used it to
choose Nobel laureates. Like other scientific work, syn-
thesis blog posts were annotated in a structure searchable
format. (ScienceDigg simply ignored posts which were not
properly annotated.) Thus it only took the AA a few sec-
onds to identify a number of promising routes. These were
instantly cross-referenced against available reagents and a
request was posted to CollabNet. Sanjay was sure that he
would get a quick response from both eager academics and
privateers. He hoped that his collaborators would—as was
usually but not always the case—simply want shared
authorship rather than a slice of the IP.
Of course, the compounds were of little value if they
couldn’t be formulated. Sanjay was pressed for time, and
nanobot development still took several weeks, so he had to
go ‘‘old school.’’ Sanjay accessed World Crystallography
Repository’s (WCR) formulation suite and entered the 2D
structures of his compounds. The system linked to the
Amazon Hyper-Cloud and initiated a series of quantum
chemical calculations to develop a custom force field for
the solid phase simulations. Unfortunately the preliminary
results were disappointing, even after more than 100 mil-
lion combinations of excipients, particle sizes, focusing
tails, and polymorphs had been analyzed in detail. He
would run a more complete search overnight, but the
chances were that the 10-min simulation was telling him
what he needed to know: don’t expect these exact com-
pounds to be quite right.
But there was a more serious problem. He had pulled up
Paolo’s biosimulator module and noticed that the doses
required to shut down those network nodes were high. He
could get around the problem, perhaps, by a complete
redesign into a single agent that selectively blocked those
three enzymatic functions.
Sanjay switched to the WCR’s Protein Analysis Tools, a
suite of Open Source software tools developed over the
past 5 years, and selected the comparison module. A voice
command brought back the pathway map he had been
looking at previously and color-coded the targets with
high-resolution NMR structures. Structures were only
available for two of the three proteins so he had the system
build a homology model for the third. Sanjay then tapped
the three structures, and a superposition of the binding sites
appeared in front of him with the common features flagged.
The static structures appeared to superimpose nicely, but a
few seconds of real-time molecular dynamics showed a
loop movement that would be problematic on one of the
three proteins.
Sanjay didn’t see an obvious work-around; the sites
were just too different. Low odds, and the compounds
weren’t straightforward to make—it could take more than a
few months to answer the question. What about an old-
fashioned approach—just design three separate new mol-
ecules and link them? That could work—but the doses
were still high. It just smelled wrong. As he was reaching
this conclusion, the AA chimed, and up popped summaries
of quite a few patents and reports of competitive programs
against two of the three targets. That’s it, Sanjay thought;
this is just not the way to go. He sipped his coffee.
It figured, he reflected. Clearly these weren’t the best
targets—anyone willing to do a little straightforward dig-
ging could have seen that—but these dorks in their fantasy
worlds never had any common sense. But that was OK; it
just made things a little more interesting. The biology was
still sound. He could always start from the nodal network
analysis that the nerd had done in the first place. Sanjay
checked his contacts log—Dmitri Yuvenovich. He hadn’t
noticed the Russian accent, a fact he chalked up to beer and
the loud Death Skaggai music at the party. He had the AA
set up a videolink to Dmitri, whose visage, 39 life size,
filled his picture window.
‘‘Hi Sanjay,’’ Dmitri smiled in a superior kind of way.
‘‘—have you fully recovered from the party? I didn’t
expect to hear from you until next week.’’
Sanjay kept his face impassive although he supposed
that the neuromuscular analyzers in Dmitri’s system would
detect the faint surprise tinged with annoyance. Fighting
back his desire to punch Dmitri’s skinny face, he kept his
voice level. ‘‘No, no, Dmitri,’’ Sanjay laughed. ‘‘I didn’t
drink as much as you think. I’ve been looking into the
gamma-schiz networks,’’ he continued. ‘‘I’m not sure the
three-target combo you mentioned is quite the best
approach, but I love the concept of finding some way to
adjust the signaling in these subsystems. I was wondering if
I could look at your nodal network maps.’’ He paused to
see how Dmitri would react. Normally junior faculty would
jump at a request like this—a chance to grab a piece of his
magic. But Dmitri merely nodded. ‘‘Sure, Sanjay. I’ve just
sent it to you—you should have it coming up now.’’ Sanjay
noted the incoming signal and accepted. A 4D roadmap,
slowly rotating, filled the right side of the picture window.
It was more complex than Sanjay had expected, with
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embedded links to 17 different datasets used to validate the
map. He realized with a shock that full genetic and epi-
genetic data from 43 million humans had been integrated to
build the maps. Where would Dmitri have obtained all this
information? While he was pondering this it dawned on
him that Dmitri was speaking again. ‘‘Of course the three-
target combo I mentioned was just to give you a sense for
the broad strategy. That was my first idea, a month ago, but
it didn’t hold up to scrutiny—I wouldn’t be surprised if you
carried out much the same analysis that I did and rejected it
for the same reasons. Of course you know more chemistry
by far than I do, but my SimChem modules generally fill in
for the holes in my experience.’’ He smiled again. ‘‘Mind if
I drive?’’ Sanjay signaled his acceptance and the AA
transferred control.
‘‘In fact,’’ Dmitri continued, ‘‘I think the best tactic is to
turn down the interaction of this transcription factor’’—a
protein popped out of one node on the map—‘‘with that
protein’’—another protein materialized—‘‘and this stretch
of DNA.’’ A 3D model of the complex assembled in front
of him, slowly rotating, with the most likely binding sites
and points of intervention highlighted. ‘‘Of course, you
only want to disrupt this interaction in the hippocampus,
and only when D7 receptor functioning is high.’’ The rel-
evant pathway maps showed the effects of the blockage on
downstream signaling. ‘‘Oh, and naturally you also want to
turn down oxphos in the mitochondria. So we need either a
single molecule that can do both things, or a two-drug
combo.’’ Sanjay was surprised at this level of detail. Who
the hell was Dmitri?
It was then that Sanjay began to notice some of the
details in view behind Dmitri. The room was enormous and
from the view of London in the background, the kid lived
in the most expensive part of the city. And it looked like a
real wood floor. How could the nerd live so well on a junior
faculty salary? At that moment, as if by cue, across the field
of view a lovely young woman glided—tall and graceful.
Dmitri noticed Sanjay’s eyes tracking the movement, and
no doubt his neuromuscular analyzers registered the
unspoken question. ‘‘No,’’ he smiled again, ‘‘it’s not my
girlfriend; it’s a Lexus9000. Do you like her?’’ Sanjay was
speechless. The Lexus9000 was the latest companion bot,
one of the really expensive models with the high emotional
intelligence. They were staggeringly expensive—at least
triple Sanjay’s full professor salary and probably six times
what Dmitri made. What the hell?
Dmitri gave him a few seconds to process this infor-
mation before continuing. ‘‘Sanjay, I should tell you I’ve
already patented all this information. I’d love to have you
do the mopping up experiments…’’—‘‘you bastard!’’
Sanjay managed not to say—‘‘…to refine the therapy. I
could do it myself, but you’re better at the chemical details,
and I’ve got a lot of other projects I need to work on
anyway. I’ll be glad to cut you in for 20% of any out-
licensing revenues. But I’m the PI on the grants and I write
up the results for my blog. Hope we can work together.’’
He flashed that superior smile again, then signed off
without waiting for a response. The darkness was replaced
by the only slightly less depressing grey of the London
afternoon as the windows gradually regained their
transparency.
For the second time in less than a minute Sanjay was
speechless. He stared out at the skyline while he tried to
collect his thoughts. He then launched a level three search
on Dmitri, his fingers stabbing the commands into the air in
front of his face. Two heartbeats later, up popped Dmitri’s
face (Sanjay groaned inwardly) while a detailed bio
scrolled down the screen. This was followed by a list of
more than 100 patent applications, 17 of which, the AA
noted, covered a range of psychiatric therapeutics and
networks. A few seconds later, the financial analysis
summary appeared, a flashing box catching his attention.
Dmitri for the past 3 years had been a consultant for Cer-
ebraDyne. And based on the overlap of his publications and
conferences with senior CerebraDyne officials, it was a
safe bet that he had licensed all of the IP to them. Ah, that
explains where all the money comes from.
Should he pursue this? Walk away? He was not used to
playing second fiddle, but if this kid (Sanjay had subcon-
sciously shifted away from ‘‘nerd’’) was right, this could be
an enormously valuable therapy. These were the few
remaining hard-core schizophrenic patients. Healthcare
agencies and private insurers—not to mention cops and
politicians and school superintendents—would pay through
the nose to fix these people. And getting a connection to
CerebraDyne could be hugely valuable.
In the end, Sanjay’s competitive nature won out. There
was no way that he was going to let Dmitri win. After all,
Sanjay was a ‘‘drug hunter,’’ a species that had been rare
for more than 100 years. He remembered that Paul, one of
his students in the Republic of Texas, had developed a new
algorithm for selectively enumerating all of the chemical
reactions stored in the public BeilPubCAS repository.
Sanjay accessed Paul’s Python code and deployed it onto
the Amazon Hyper-Cloud. He then accessed the existing
structures from the WCR and cross-referenced these
against experimental data for available compounds and
related targets. With the structures in hand, Sanjay ran the
WCR’s AutoStere protocol to identify potential isosteric
binding sites in the structures of interest. The virtual teth-
ering protocol identified a site that might be able to restrict
the loop movement and allow him to design a single agent
to block both targets.
With the structures and custom function in hand, Sanjay
was ready to initiate the docking study. But despite recent
advances in the TIP32P** water model, Sanjay still didn’t
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completely trust the predicted protein-ligand binding ener-
getics. Next, he transferred the experimental data into the
Google Predictive Analytics engine and quickly designed a
new empirical function to fit the experimental data. Now he
launched the dynamic docking simulator, dropping the
empirical function into the hopper. He always preferred to run
his docking simulations using the slow protocols that incor-
porated solvated dynamics—‘‘less haste less waste,’’ as his
107-year-old grandmother still liked to say as she carefully
pruned her rose bushes. A progress bar appeared in front of
him showing ‘‘1030 molecules remaining, 2,704 h 15 min to
completion.’’ Sanjay quickly stopped the process and con-
strained the search to only those molecules that fell within the
applicability domain of his empirical function. This reduced
the search to 1012 molecules and allowed the analysis to
complete in a few minutes.
After a bit of visual inspection to confirm the results of his
docking study, Sanjay moved on to the next step. He knew that
slow binding kinetics could provide a means of lowering the
dose for his compound. To check this, he ran a few seconds of
real-time MD on each of the top 50,000 hits from the docking
study. A quick scan of the results turned up 620 structures that
appeared to have the required residence time. Sanjay submitted
all these structures to PPKPDS, the Primate Pharmacokinetic
and Pharmacodynamic Simulator, a project developed through
a collaboration of industry, academia, and the World Drug
Approval Agency. Of the compounds submitted, 52 appeared
to have the necessary PK profile, including the ability to be
actively transported into the brain. All but a few were predicted
to be readily synthesizable. He felt satisfied that he could turn
this problem over to his network of students.
There was one last step before he could stop for the day.
Sanjay launched the automatic patent submission app,
Patent Rationalizer, which recommended that he add a
handful of other compounds (15 to be exact) to the 52
molecules on his short list, based on chemical changes
compatible with various alternate routes of administration
that could be desirable for certain patients. As usual, PatRat
did a comprehensive search against the 279 million
chemical patents stored in its database. The days when
there was any ambiguity about whether one patent over-
lapped another were long gone, as were the days when
patents covered zillions of completely irrelevant com-
pounds. All of his 67 molecules were clean, and after
answering a few questions about the details of how the
claims should be structured, he hit the submit button. A few
seconds later he received notification that the World Patent
Clearinghouse had received the documents and were sub-
mitting them in the appropriate mix of formats and lan-
guages to the various patent offices around the globe.
By early March Sanjay thought he had the problem licked.
The 27th molecule had excellent properties—reliable pre-
dictions of good brain uptake and low human dose; novelty;
the expected response against all the targeted biomarkers;
limited off-target signaling. Admittedly, the mitochondrial
gene response profile to elevated pH was not quite as sharp he
would have liked, but for a first-in-class approach it was more
than sufficient; patients would likely see the effects within a
day or two. It was ready to go into the obligate trans-species
experiments that were still required because up to 5% of the
time the in vitro and computational models proved inaccurate,
and the cowardly politicians feared repercussions if ‘‘someone
got hurt.’’ The animal experiments, of course, did definitely
hurt a lot of people, who suffered needlessly during the delay,
but the gutless politicians’ didn’t care—their hands were
clean. Of course, the fact that the humanized primates lived
like kings, with active lifespans projected to be longer than a
century, helped assuage everyone’s guilt over these experi-
ments, but this remained the single most distasteful part of the
job. Still, there was nothing that could be done about it if you
wanted your drug approved anywhere in the world except the
Nordic Alliance or California. Sanjay instructed the AA to
program the flow reactor systems to crank out a few kilos over
the weekend. By the middle of the following week all the
necessary QA was complete, and the compound was shipped
out to the Singapore humate colonies.
By the end of August the animal experiments and for-
mulations work were completed, and S27 looked to be on
track for human studies. But Sanjay, during the preceding
months, had slowly come to realize that he was mostly
going to be observing from the sidelines. The contract he
had signed with CerebraDyne was explicit—they wanted
him to hand over the molecule and stand back. His pride
required him to ask about the clinical path for the molecule,
and grudgingly the CerebraDyne people had shown him
their plans. He had to admit that the clinical simulations
were breathtakingly complex—they had simulated 14
million different strategies for running the trials—and if
CerebraDyne could pull this off, they’d have all the data
they needed for a provisional approval within 12 months.
There really wasn’t anything for him to do. He had also
come to appreciate the intensive role that Dmitri was
playing, not just on this project, but also on quite a few
others at CerebraDyne. Sanjay had poked a bit into these
other projects, but Dmitri seemed uninterested in expand-
ing their collaboration. Resigned, Sanjay went back to his
old ideas for nano-delivery of combination medicines to
damaged heart muscle and continued writing his grants.
It was a few months later at the faculty New Year’s Eve
party that Sanjay again ran into Dmitri. Sanjay had actually
been looking for him this time. He hadn’t been able to get
any answers from the CerebraDyne flacks about how the
clinical trials were going, and he hoped Dmitri could fill
him in. Fortunately the band this year was more into the
latest trend, a sort of acoustic punk metal infused with the
obligatory cello and punctuated by the latest trendy
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instrument, the neuro-kalimba. Whatever. It wasn’t as
likely to sterilize hamsters as Death Skaggai, and it was
barely possible to actually hold a conversation. He pulled
Dmitri away from his ‘‘date,’’ which appeared to be one of
the rumored prototype Lexus10Ks. Even the M6 spooks
supposedly hadn’t gotten their test model yet. She pouted
slightly for effect but then turned away and cast a jaundiced
eye over the room, looking for suitably interesting test
subjects. Sanjay wondered what had happened to the 9,000
model but decided not to ask.
‘‘Dmitri!’’ Sanjay shouted. The music wasn’t that quiet.
‘‘What’s happening to S27? When is CerebraDyne going to
release the results? When should the drug get approved?’’
Dmitri gave his maddening smile and beckoned to
Sanjay. Come with me. They walked towards the faculty
lounge, their footsteps echoing down the long, empty
corridor. Glowing Festus greenery hung from all the light
fixtures, casting wild shadows in all directions. They
entered the lounge and Dmitri closed the door behind them,
the music now dim in the distance. The high-ceilinged
room, a loving homage to Darwin’s study, was of course
empty, the workstations and computer screens dark. Dmitri
glanced around and said, ‘‘Better to talk outside. I don’t
think it’s that cold, although there’s a 59% chance of snow
later.’’ He led the way through the tall French doors out to
the private patio that looked out over the University
grounds.
He paused for a second. ‘‘Sanjay,’’ he began, ‘‘techni-
cally I’m not supposed to be telling you this, but I think
you deserve to know.’’ He paused again, looking down the
hill rather than at Sanjay. ‘‘CerebraDyne simultaneously
ran gamma-schiz clinical trials on three different strategies
this summer. They kept the whole thing under the table.
Yours was the first; a second came from Bangalore, and the
third came from Beijing. The CerebraDyne crew has been
assisting me’’—Sanjay blinked at this—‘‘in the analysis of
the results from all three trials. There’s no question, the
compound from Bangalore is the best. It’s really quite
amazing.’’ Something close to animation came into his
robotic inflection. ‘‘They managed to do exactly what my
simulations called for—they designed a nano-factory that
only released the drug cargo when necessary, and with
pinpoint control.’’ Dmitri seemed almost aroused by the
thought. ‘‘So they achieved more complete disease modi-
fication at lower doses. The cost of goods is higher but the
pharmacoeconomics support their strategy.’’ Dmitri smiled
and went on. ‘‘The Chinese went for broke with a cellular
strategy. I bet in a decade this will be the preferred
approach, but for now they still have trouble optimizing
delivery to the hippocampus. As a result, their control of
symptoms was more sketchy and the nanobot images
suggested less disease modification than either of the other
strategies.’’
Sanjay regained his voice. ‘‘So what happens to my
compound?’’
Dmitri smiled. ‘‘Well, there’s nothing wrong with it, but
in light of the success of this new delivery paradigm, there
is really no future for those kinds of molecules any more.
CerebraDyne doesn’t even want to retain the rights; it’s
yours for the taking. You might be able to sell it to one of
the low-cost shops that peddle drugs to the poorest coun-
tries. Certainly you should still be able to publish the data
and use that to help support your next grant application.’’
Dmitri paused again, then tentatively put out a hand to the
older man’s shoulder. Sanjay shuddered involuntarily but
didn’t move. ‘‘If you need any help writing up the results
for your blog, let me know.’’ He glanced back into the
faculty lounge and through the glass noticed a lithe form in
the shadows. ‘‘Well, I think that’s about it. See you, San-
jay.’’ And with that, Dmitri went back inside, leaving
Sanjay staring after him and his companion returning to the
party, walking arm in arm. He was startled by the kiss of
cold, wet snowflakes on his cheek.
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